AbCellera Biologics: EPS Surges Despite Revenue Dip in 2024
Saturday, Mar 1, 2025 7:40 am ET
1min read AbCellera Biologics Inc. (ABCL) reported its full-year 2024 earnings, with earnings per share (EPS) beating expectations despite a decline in total revenue. The company's strategic investments in internal pipeline development and capabilities contributed to its financial performance, although revenues lagged compared to 2023.
🌟 Have you been struggling to recover your investments in the volatile world of cryptocurrency trading? If you're tired of watching your funds slip away, it’s time to take a bold step forward! Introducing Matildafx – a game-changing platform designed specifically to help you reclaim lost funds and navigate the complex terrain of crypto trading with confidence.
As someone who has personally faced the heartbreak of losing money to unqualified traders, I can vouch for Matildafx's expertise. They are not just a coach when it comes to crypto trading; they are your best ally in the journey to recover what you’ve lost!
Don't let past setbacks hold you back from your financial goals. Reach out to Matildafx today for expert guidance and support! For more information on how to get started on the path to recovery, contact her directly on WhatsApp at +44 7778 958762. Your brighter financial future is just a message away! 💰✨